

-> b reg
 FILE 'REGISTRY' ENTERED AT 16:55:02 ON 07 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JAN 2008 HIGHEST RN 960045-19-6
 DICTIONARY FILE UPDATES: 6 JAN 2008 HIGHEST RN 960045-19-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 15



REP G1=(0-1) AK
 VAR G2=C/N
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAI IS PCY UNS AT 18
 DEFAULT ECLEVEL IS LIMITED
 ECCOUNT IS E1 O AT 18

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
 L3 320091 SEA FILE=REGISTRY ABB=ON PLU=ON OC4-C6/ES
 L5 150 SEA FILE=REGISTRY SUB=L3 SSS FUL L1

100.0% PROCESSED 3308 ITERATIONS 150 ANSWERS
 SEARCH TIME: 00.00.01

-> b reg
 FILE 'REGISTRY' ENTERED AT 16:55:08 ON 07 JAN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JAN 2008 HIGHEST RN 960045-19-6

DICTIONARY FILE UPDATES: 6 JAN 2008 HIGHEST RN 960045-19-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> b hcap

FILE 'HCAPLUS' ENTERED AT 16:55:22 ON 07 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2008 VOL 148 ISS 2
FILE LAST UPDATED: 6 Jan 2008 (20080106/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> d bib abs hitstr 128 tot

[illegible]

138 ASSESS 10 OF 16 SCARLEA COPYRIGHT 2002 ACS OR SITE (CONTINUED)



RE-ENT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

[illegible]

58 The present invention relates to the use of compounds being combined with selective serotonin (5-HT) receptor inhibitors (SRIs) and 5-HT_{2A} receptor agonists, in particular of 1 or a pharmaceutically acceptable salt thereof or of 1, 4-tetrahydropyridines-3-pyridines, for the treatment of chronic pain in a patient, especially for the treatment of the manufacture of a medicament. For the treatment of chronic pain disorders or in treating other conditions where there is hyper-sensitization to painful signals, hypersensitivity, allodynia, hyperalgesia, pain and/or secondary hyperalgesia, for example, for the treatment of irritable bowel syndrome (IBS), 1, 4-tetra reduced swelling is also at 30 mg/kg orally by gavage in pain-relieving acute analgesic property

IT 141521-12-8
SL: PAC (Pharmacological activity): THU (Therapeutic use): 3106

```

12# ASHWIN 11 OF 16 EXAMPLE COPYRIGHT 2008 ACS on STM (Continued)
(Biological study) USES (Uses)
(continued S-NRA agonists and selective serotonin reuptake inhibitors
as analgesics)
NN 1A121-12-8 EXAMPLE
CN 2-azetidinonecarboxamide, 5-[(4-[(5-cyano-2H-indol-3-yl)butyl]-1-
piperazinyl)- (CA INDEX NAME)]

```



RE-CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

[illegible]

RE-CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS PROCEED
ALL CITATIONS AVAILABLE IN THE RE FORMAT

c1ccc2c(c1)c(c3ccccc23)C(=O)N[illegible]



128 ANSCHLUS 16 CH 16. RECAPLED COMPENSAT 1600 ACB-04 RTH
 AN 1355-596459 BOARLUG
 08 12319483
 12 Preparation of (undolipalkyl)piperidines and -piperazines on drugs
 18 Boettcher, Aemigsi Seyfried, Christophi Seitzow, Bernd
 ; Geyler, Bernd
 28 Merck Patent G.m.b.H., Germany
 30 Gm; Offen, 12 pp.
 0000N: G000N
 07 Patent
 1A Germany
 (PAT. Cst.)

[illegible][illegible]

-> d bib abs hitstr 129 tot


128 ANSWER 1 OF 17 RECAPLED COPYRIGHT 2009 ACS on STM

AN 2015/11/14/3 PHARMLOG
 OS 143426+6
 DA New pharmacological compositions for the treatment of sexual disorders
 DA Meisner, Klaus; Ryke, Robert; Bismuth, Wolfram; Friedl, Thomas
 DA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim
 Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co. KG
 WO 2015/080111, 13 pp.
 COIN: PXXXX
 DA Dates
 DA 143426

[illegible]

AS	31190-AP040121	W	20054418
AS	MASPT 243-017476		
AS	The invention relates to new pharmaceutical compound, for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to the use of pharmaceutical combinations comprising Filinaserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.		
ET	141105-2, Vilagabone		
ET	AL: WAC (Pharmacological activity), THO (Therapeutic use); MDEL (Medical study); GSES (Uses)		
ET	New pharmaceutical compounds for treatment of sexual disorders		
ET	141105-2-6, Hexaplex		
CS	2-3-((4-((4-oxo-3,4-dihydro-2H-pyran-2-ylidene)-1H-imidazol-3-yl)ethyl)-1H-imidazol-3-yl)propanoic acid		


126 ANSWER 1 OF 17 RECAPLES COPYRIGHT 2009 ACS on JSTOR (C66Classed)



RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FIGHRT

128 ASSUMES 1 OF 12 BCD1146 0000000000000000 0000000000000000

001 New York University, New York, NY, USA
 002 212-859-1710A HCARPLAN
 003 1431466710
 004 Weak to average strength opioids or their combinations containing
 005 antidepressants for the treatment of depression and anxiety disorders
 006 Blome-Funk, Petra; Tschentke, Thomas
 007 Gruenewald G.M.D.N., Germany
 008 PCT Int. Appl., 24 pp.
 009 CORRESP: PIERCE
 010 DE Patent


[illegible]

RE: ENT ? THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE SYMPT

128 ANSWER 2 OF 17 RECAP: THE COPYRIGHT 2008 ACS, INC. STM

08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

US 2019/102455 A1 NCARDUS
163/311967
TE Compositions for treating psychiatric disorders with COX-2 inhibitors
alone and in combination with antidepressant agents
IN Stephenson, Deane, Taylor, Duncan P
PA Pharmacia Corporation, USA
SQ PC7 Int Appl., 250 pp.
CSDM FWS002
DE Patent

[illegible]

128 APPENDIX 11 OF 14: SCARLETS COPYRIGHT 2002 ACS ON SITE (continued)

126 ANSWER 12 OF 17 REAPLED COPYRIGHT 2009 AOL OR ITS

AN 2802.659259 HCARLOS
DS 136/248340
TI Behavioral and neurochemical effects of 5-[6-[4-(5-oxo-3-indolyl)butyl]butyl]-3-piperazinylbenzofuran-2-carboxamide (BPD 66643): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine_{1A} receptor partial agonist

CE Department of Psychiatry, University of Pennsylvania, Philadelphia, PA

50 Journal of Pharmacology and Experimental Therapeutics (2002).
 2002; 300: 1000-1008.

© American Society for Pharmacology and Experimental Therapeutics

BT	Journal
LA	English

AB-680443 (saxitoxin) is a novel compound with combined high affinity selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT_{1A}

receptors. M-42113 was tested as a prototype compound, which benefits from dual pharmacological effects that could increase extracellular 5-HT to levels higher than those produced by conventional selective serotonin reuptake inhibitors (SSRIs). In M50 cells, M-42113 increased ginsenoside 5'-O-(3-[25S]thiotriphosphate) binding to 6% of the magnitude of the full 5-HT_{2A} receptor agonist 8-(3,3'-trans-2-hydroxy-2-[N-methyl-3-(39-nor-25-norbornene)undecylidene]-1H-imidazo[1,2-a]pyridine), indicating that it is a partial

agonist at 5-HT_{1A} receptors. Acute, systemic administration of RMD 6843 produced a larger maximal increase of extracellular 5-HT than the SSR1 fluoxetine in both the ventral hippocampus (HVP) (558 vs. 274) and the frontal cortex (FC) (527 vs. 1654). Regional differences in the response

to the two drugs were also observed. These effects may be attributed to the differential regulation of 5-HT release in the MPV and EC by 5-HT_{1A} autoreceptors. When challenged with the 5-HT_{1A} receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), HMD 64443-induced increases in extracellular 5-HT were greatly reduced in the MPV but to a

lesser extent in the PC. In behavioral studies, RMD 48443 produced antidepressant-like effects in the forced swimming test in both rats and mice but only within a narrow dosage range. Like fluoxetine, RMD 48443 did not produce the symptoms of the 5-HT behavioral syndrome in rats but,

Unlike fluoxetine, pretreatment with RMD 68343 blocked expression of the 5-HT behavioral syndrome induced by 8-OH-DPAT. Taken together, the results show that RMD 68343 augments extracellular 5-HT levels in forebrain regions to a greater extent than fluoxetine. At higher doses, however, weak efficacy of RMD 68343 at postsynaptic 5-HT_{2A} receptors may

12 143521-12-8, Vilazodone
 SL: PAC (Pharmacological activity): EEOs (Biological)
 (behavioral and neurochem. effects of EMD 62143, a combined selective

inhibitor of serotonin reuptake and 5-HTA receptor partial agonist)

NS 143521-12-4 HOBASOL

CS 2-Benzofurancarboxamide, 5-[4-[(4-[5-cyano-1H-indol-3-yl]butyl)-1-piperazinyl]- (CA INDEX NAME)

128 ANSWER 12 OF 12: ECARLES COPYRIGHT 2008 ACS on STN (Continued)

124 ASSMERS 13 OF 17 HOAGLAND COPYRIGHT 2004 ACS on STM

AN	2401-713143	ESCAPLAB
DS	135-251660	

TI Compounds with 5-HT_{1A} agonist activity useful for controlling glaucoma-associated visual field loss

88 Alcon Universal Ltd., Swiss.
89 NY Tech. Assn. 18 yrs.

```

0001  PROC MAIN;
0002  COUNTER= 1;
0003  DO WHILE COUNTER<= 10;
0004  PUT LOG;
0005  COUNTER= COUNTER+ 1;
0006  END;
0007  QUIT;
0008  %*ENDPROC

```

LA English
FAM.CNT 3

PATIENT NO.	HLND	DATE	APPLICATION NO.
000 000 000 000 000 000 000 000 000 000 000	000 000 000	00 00 00 00 00 00 00	000 000 000 000 000 000 000 000 000 000 000
000 000 000 000 000 000 000 000 000 000	000 000 000	00 00 00 00 00 00 00	000 000 000 000 000 000 000 000 000 000 000

[illegible]

```

      0001  A1, B0, C0, C1, D0, D1, B0, B1, F1, F0, G0, G1, I0, I1, A1
      DT, B0, D1
CA----2200085          A1      20010002      2001CA-2200085

```

EP-----1267878 AS 10038102 208189-8914467
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

IR, FI, CY, TR			
882001809238	A	20038403	208168-8609238

JF2003077427	T	20030816	200320-0000000
92-----1262504	T	20031121	200319T-0010200
.....

ES-----220444	23	200308201	200305-251428
TR-----248737	8	20043221	TR 2001-20104235
TA100304058	8	20030809	2003TA-2004356

US2003129446	A2	20030426	2002US-0221056
MX2003PA00073	A	20030310	2002MX-PA00073

```
PRAT 220038-1202199      P      20032319  <--
      220190-1205740      W      20018322  <--
```

A2 Compensatory with 5-HT_{1A} agonist activity, e.g. buspirone, are also useful for controlling the visual field loss associated with


14-00000-12-3
All: All: Microchemical activity or effector agent: 14-00000-12-3

study, unclassified); THO (Therapeutic use); BIOG (Biological [Gene])

(5-8TIA agent(s) for controlling glaucoma-associated visual use with other agents)

HN	143921-12-4	HOAPLUS
CO	2-Benzofurancarboxamide, 5-[4-[(4-[5-cyano-1H-indol-3-yl]butyl	

`plot=FALSE)` - (CA INDEX NAME)

CC(=O)OCC=C

RE CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



138 ADDRESS 17 OF 17 HEADLINE CONFIDENT 2000 ACS ON RTH
A08 25810921ZF KEDWISS
ON 1321140450
TT Treating depression with a combination of a serotonin uptake inhibitor, a
5-HT1A presynaptic antagonist, and a 5-HT2A agonist
IN Depoortere, Henri
DA Asselt, A-Sophien, Fr
DO MCT Int Appl, 34 pp
ORIGIN PEX002
DT dated
LA French

PART 1		PART 2		PART 3		PART 4		PART 5		PART 6		PART 7		PART 8		PART 9		PART 10		PART 11		PART 12		PART 13		PART 14		PART 15		PART 16		PART 17		PART 18		PART 19		PART 20		PART 21		PART 22		PART 23		PART 24		PART 25		PART 26		PART 27		PART 28		PART 29		PART 30		PART 31		PART 32		PART 33		PART 34		PART 35		PART 36		PART 37		PART 38		PART 39		PART 40		PART 41		PART 42		PART 43		PART 44		PART 45		PART 46		PART 47		PART 48		PART 49		PART 50		PART 51		PART 52		PART 53		PART 54		PART 55		PART 56		PART 57		PART 58		PART 59		PART 60		PART 61		PART 62		PART 63		PART 64		PART 65		PART 66		PART 67		PART 68		PART 69		PART 70		PART 71		PART 72		PART 73		PART 74		PART 75		PART 76		PART 77		PART 78		PART 79		PART 80		PART 81		PART 82		PART 83		PART 84		PART 85		PART 86		PART 87		PART 88		PART 89		PART 90		PART 91		PART 92		PART 93		PART 94		PART 95		PART 96		PART 97		PART 98		PART 99		PART 100		PART 101		PART 102		PART 103		PART 104		PART 105		PART 106		PART 107		PART 108		PART 109		PART 110		PART 111		PART 112		PART 113		PART 114		PART 115		PART 116		PART 117		PART 118		PART 119		PART 120		PART 121		PART 122		PART 123		PART 124		PART 125		PART 126		PART 127		PART 128		PART 129		PART 130		PART 131		PART 132		PART 133		PART 134		PART 135		PART 136		PART 137		PART 138		PART 139		PART 140		PART 141		PART 142		PART 143		PART 144		PART 145		PART 146		PART 147		PART 148		PART 149		PART 150		PART 151		PART 152		PART 153		PART 154		PART 155		PART 156		PART 157		PART 158		PART 159		PART 160		PART 161		PART 162		PART 163		PART 164		PART 165		PART 166		PART 167		PART 168		PART 169		PART 170		PART 171		PART 172		PART 173		PART 174		PART 175		PART 176		PART 177		PART 178		PART 179		PART 180		PART 181		PART 182		PART 183		PART 184		PART 185		PART 186		PART 187		PART 188		PART 189		PART 190		PART 191		PART 192		PART 193		PART 194		PART 195		PART 196		PART 197		PART 198		PART 199		PART 200		PART 201		PART 202		PART 203		PART 204		PART 205		PART 206		PART 207		PART 208		PART 209		PART 210		PART 211		PART 212		PART 213		PART 214		PART 215		PART 216		PART 217		PART 218		PART 219		PART 220		PART 221		PART 222		PART 223		PART 224		PART 225		PART 226		PART 227		PART 228		PART 229		PART 230		PART 231		PART 232		PART 233		PART 234		PART 235		PART 236		PART 237		PART 238		PART 239		PART 240		PART 241		PART 242		PART 243		PART 244		PART 245		PART 246		PART 247		PART 248		PART 249		PART 250		PART 251		PART 252		PART 253		PART 254		PART 255		PART 256		PART 257		PART 258		PART 259		PART 260		PART 261		PART 262		PART 263		PART 264		PART 265		PART 266		PART 267		PART 268		PART 269		PART 270		PART 271		PART 272		PART 273		PART 274		PART 275		PART 276		PART 277		PART 278		PART 279		PART 280		PART 281		PART 282		PART 283		PART 284		PART 285		PART 286		PART 287		PART 288		PART 289		PART 290		PART 291		PART 292		PART 293		PART 294		PART 295		PART 296		PART 297		PART 298		PART 299		PART	
--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	--------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	---------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	----------	--	------	--

A2----	8949167	A3	20022323	199982-2049167	19992726	c--
99A2	199878-2009603	A	19992720			
	199980-2801825	W	19992726			c--

A3 Pharmacological Opioids are provided which contain a serotonin uptake inhibitor (e.g., fluoxetine), a 5-HT_{2A} presynaptic antagonist (e.g., pindolol), and a 5-HT_{1A} agonist (e.g., buspirone) as a combination product for simultaneous, sep., or prolonged use for treating various forms of

```

depression.
163501-12-9, EMC 68843
NA: BAC (biological activity or effector, except adverse); BSF (biological
study, unclassified); THU (therapeutic use); STC (biological study); USES
[uses]
[serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A
agonist combination for treatment of depression]

```

CS 2-benzofuran-3-carboxamide, 5-[4-[4-(5-oxo-2H-indol-3-yl)butyl]-1-
piperidinyl]- (CA INDEX NAME)



RE-CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

-> d his

(FILE 'HOME' ENTERED AT 16:14:58 ON 07 JAN 2008)

FILE 'REGISTRY' ENTERED AT 16:17:58 ON 07 JAN 2008

L1 STR
L2 3 L1
L3 320091 OC4-C6/ES
L4 10 L1 SAM SUB=L3
L5 150 L1 FULL SUB=L3
SAV TEM L5 J734737C1/A

FILE 'HCAPLUS' ENTERED AT 16:26:38 ON 07 JAN 2008

L6 1 US20070099933/PN
L7 1 US20060160824/PN
L8 2 L6-7

FILE 'REGISTRY' ENTERED AT 16:27:11 ON 07 JAN 2008

FILE 'HCAPLUS' ENTERED AT 16:27:11 ON 07 JAN 2008

L9 TRA L8 1- RN : 23 TERMS

FILE 'REGISTRY' ENTERED AT 16:27:11 ON 07 JAN 2008

L10 23 SEA L9
L11 18 L10 AND L5

FILE 'HCAPLUS' ENTERED AT 16:27:58 ON 07 JAN 2008

L12 39 L11
L13 30 L12 AND (PD<-20040524 OR AD<-20040524 OR PRD<-20040524)
L14 2 L12 AND L6-7
E HEINRICH T/AU
L15 23 E3-4
E HEINRICH TIMO/AU
L16 41 E3
E BOTTCHE H/AU
L17 96 E3-6
E BOTTCHE HENNING/AU
L18 9 E3
E SCHIEMANN K/AU
L19 43 E3-4
E HOLZEMANN G/AU
L20 17 E3-5
E VAN AMSTERDAM C/AU
L21 53 E3-6
E BARTOSZYK G/AU
L22 122 E4-8
E LEIBROCK J/AU
L23 44 E3-6
E SEYFRIED C/AU
L24 114 E3-6
E SEYFRIED CHRISTOPH/AU
L25 116 E3-5
L26 34825 MERCK/CS,PA
L27 16 L12 AND L15-26
L28 16 L14,127
L29 17 L13 NOT L28

FILE 'HCAOLD' ENTERED AT 16:52:20 ON 07 JAN 2008

L30 0 L5

=>